14213-13-9

Usage

Uses

Used in Pharmaceutical Research:
4-(1H-TETRAZOL-1-YL)ANILINE HYDROCHLORIDE is used as a building block for the development of new drugs due to its potential application in medicinal chemistry.
Used in Organic Synthesis:
4-(1H-TETRAZOL-1-YL)ANILINE HYDROCHLORIDE is used as an intermediate in the synthesis of various organic compounds, contributing to the creation of diverse chemical entities.
Used in Antimicrobial Applications:
4-(1H-Tetrazol-1-yl)aniline hydrochloride is used as an antimicrobial agent, leveraging its properties to combat microbial infections.
Used in Antitumor Applications:
4-(1H-Tetrazol-1-yl)aniline hydrochloride is used as an antitumor agent, being investigated for its potential to inhibit tumor growth and contribute to cancer treatment.

InChI:InChI=1/C7H7N5/c8-6-1-3-7(4-2-6)12-5-9-10-11-12/h1-5H,8H2

Upstream product

• 14210-30-1 5-chloro-1-(4-nitrophenyl)tetrazole 
• 288-94-8 1H-tetrazole 
• 350-46-9 4-Fluoronitrobenzene 
• 5378-52-9 phenyl-1H-tetrazole 
• 309742-07-2 N-[4-(1H-tetrazol-1-yl)phenyl]acetamide 
• 106-50-3 1,4-phenylenediamine 
• 149-73-5 trimethyl orthoformate 
• 100-01-6 4-nitro-aniline 
• 14210-25-4 5-Chloro-1-phenyltetrazole 
• 128828-52-4 N,N-dibenzyl-p-phenylenediamine 
• 65052-89-3 N,N-dibenzyl-4-nitroaniline 
• 217654-46-1 1-[4-(N,N-dibenzylamino)phenyl]-1H-tetrazole 
• 14213-11-7 1-(4-nitrophenyl)-1H-tetrazole 

Downstream Products

• 288-94-8 1H-tetrazole 
• 21788-29-4 p-phenylenebis-1H-tetrazole 
• 217654-45-0 phenyl 4-(1H-1-tetrazolyl)phenylcarbamate 
• 377079-04-4 tert-butyl N-[4-(1H-1-tetrazolyl)phenyl]glycinate 
• 377078-98-3 ethyl N-[4-(1H-1-tetrazolyl)phenyl]glycinate 
• 217654-62-1 1-(2-chloroethyl)-1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazoyl)phenyl]urea 
• 217654-58-5 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-1-(2-hydroxyethyl)-3-[4-(1H-1-tetrazoyl)phenyl]urea 
• 217654-54-1 1-(2,2-diethoxyethyl)-1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-3-[4-(1H-1-tetrazolyl)phenyl]urea 
• 333986-50-8 tert-Butyl 4-[4-(1H-Tetrazol-1-yl)anilino]-1-piperidinecarboxylate 
• 1037793-74-0 4-[4-(4-tetrazol-1-ylphenylcarbamoyl)thiazol-2-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 1240707-56-5 1-(4-azidophenyl)-1H-tetrazole 
• 1454771-60-8 C₂₂H₂₄N₈O 
• 64001-11-2 1-(4-hydroxyphenyl)-1H-1,2,3,4-tetrazole 
• 133638-21-8 4-Tetrazol-1-yl-phenyl-cyanamide 

Relevant academic research and scientific papers

Design and biological evaluation of tetrahydropyridine derivatives as novel human GPR119 agonists

A series of novel tetrahydropyridine derivatives were prepared and evaluated using cell-based measurements. Systematic optimization of general structure G-1 led to the identification of compound 35 (EC50 = 4.9 nM) and 37 (EC50 = 8.8 nM) with high GPR119 agonism activity and moderate clog P. Through single and long-term pharmacodynamic experiments, we found that compound 35 showed a hypoglycemic effect and may have an effect on improving basal metabolic rate in DIO mice. Both in vitro and in vivo tests indicated that compound 35 was a potential potent GPR119 agonist in allusion to T2DM treatment.

CATHEPSIN K INHIBITOR AND APPLICATION THEREOF

The invention relates to capthepsin K inhibitors and uses thereof, specifically relates to a class of compounds having the formula (I) which are used for treating or preventing cathepsin dependent diseases or conditions, specifically, wherein the cathepsin is capthepsin K. The compounds and compositions thereof can be used as bone resorption inhibitors for the treatment of associated diseases.

Synthesis and transformations of 1-(azidophenyl)-1H-tetrazoles

Diazotization of 1-(aminophenyl)-1H-tetrazoles and subsequent treatment of the diazonium salts with sodium azide gave 1-(azidophenyl)-1H-tetrazoles which were brought into cyclization with ethyl acetoacetate and cyanoacetanilide to obtain 1,2,3-triazole derivatives. Under these conditions, the tetrazole ring may undergo cleavage with formation of cyanamide group.

NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula (I) or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(=NH)NH2, which are useful as inhibitors of factor Xa.

Optically active antifungal azoles. XI. An alternative synthetic route for 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl )propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (TAK-456) and its analog

New routes for the synthesis of the optically active antifungal triazoles 1-[(1R,2R)-2-(2,4-difluorophenyl)-2-Hydroxy-1-Methyl-3-(1H-1,2,4-triazol-1-Yl )propyl]-3-[4-(1H-1-tetrazolyl)phenyl]-2-imidazolidinone (1b) and the 3-[4-(1H-1,2,3-triazol-1-Yl)phenyl]-2-imidazolidinone analog (1a) that possess an imidazolidine nucleus were established. The key synthetic intermediates, (2R,3R)-3-(2,2-diethoxyethyl)amino-2-(2,4-difluorophenyl)-1-(1H-1,2,4-triazol -1-Yl)-2-butanol (8) and (2R,3R)-2-(2,4-difluorophenyl)-3-(2-hydroxyethyl)amino-1-(1H-1,2,4-triazol-1- yl)-2-butanol (14), were prepared by the ring-Opening reaction of the oxirane (2) with the corresponding 2-Substituted ethylamines. The acetal (8) was converted to the imidazolidinones (1a, b) by condensation with the carbamates (10a, b) followed by treatment with hydrochloric acid and subsequent catalytic hydrogenation. The candidate selected for the clinical trials, 1b (TAK-456), was alternatively prepared from the hydroxyethylamino intermediate (14) via two reaction steps: condensation with the carbamate (10b) to the urea (15) and subsequent cyclization to the imidazolidinones. This newly developed synthetic route could be applied to a large scale preparation of 1b.

Optically active antifungal azoles. X. Synthesis and antifungal activity of N-[4-(azolyl)phenyl]- and N-[4-(azolylmethyl)phenyl]-N′-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy -1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-azolones

New optically active antifungal azoles, N-[4-(azolyl)phenyl]- and N-[4-(azolylmethyl)phenyl]-N′-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy -1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]azolones (1, 2, 3), were prepared in a stereocontrolled manner. Compounds 1

Nitrogen containing heteroaromatics as factor Xa inhibitors

The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein J is N or NH and D may be C(=NH)NH2, which are useful as inhibitors of factor Xa.

A kinetic investigation of the thermal rearrangement of allyloxytetrazoles to N-allyltetrazolones

The mechanism of the thermal rearrangement of 1-aryl-5-allyloxytetrazoles 1 to give 1-aryl-4-allyltetrazolones 2 in very high yield has been investigated through kinetic studies in one polar and one less polar solvent. The results suggest mainly a concerted [3,3] sigmatropic process, in which a partially positively charged allyl group migrates from oxygen to nitrogen, similar to the polar transition state found in the Claisen rearrangement.

SYNTHESIS AND PROPERTIES OF PHENYLENEBIS-1H-TETRAZOLES

Heterocyclization of m- and p-phenylenediamines with orthoformic ester and sodium azide has given phenylenebis-1H-tetrazoles.Under these conditions, o-phenylenediamine gives benzimidazole. o-, m-, and p-Phenylenebis-1H-tetrazoles were also obtained from the nitroanilines via the intermediate nitro- and aminophenyltetrazoles.The reactions of the bistetrazoles examined were basic hydrolysis, aminomethylation, and complex formation with copper salts.